Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AXNX vs AHCO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AHCO Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

AHCO Overall Winner 6-Pillar Tally: AXNX 0 – 6 AHCO Matrix Metrics: AXNX 2 – 8 AHCO

As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas AHCO carries 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin).

  • Composite vs. Pillar Nuance: While AXNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. AHCO 45.2/100 HOLD), AHCO captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (3.8% vs. N/A operating margin) and revenue trajectory (+10.9% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AXNX vs AHCO
AXNX US Equity
AXNX
Institutional Equity
$0.83
-8.28% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
52.1 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
AHCO NASDAQ Head-to-Head Winner
AdaptHealth Corp. Common Stock
Services-Home Health Care Services
$7.20
-0.69% 1D
Market Cap $989.8M
TTM Revenue $3.44B
Forward P/E 7.8x
Beta / 30D Vol 0.17β · 67% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 29.0 Fund 46.0 Flow 54.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 57
RSI-14: 57.1 · SMA20: $6.96 · SMA50: $6.32

6-Pillar Scorecard Institutional Category Breakdown (AXNX 0 – 6 AHCO)

Columns: Metric · AXNX · AHCO
1. Valuation Multiples AHCO
Forward P/E N/M 7.8x
Trailing P/E N/M 7.8x
PEG Ratio N/M N/M
EV / Revenue N/M 0.9x
2. Growth & Scale AHCO
Revenue Growth (YoY) N/A +10.9%
Earnings Growth (YoY) N/A +6.7%
TTM Revenue (USD) N/A $3.44B
Market Cap N/A $989.8M
3. Profitability & Quality AHCO
Gross Margin N/A 18.2%
Operating Margin N/A 3.8%
Net Profit Margin N/A -11.8%
Return on Equity (ROE) N/A -28.4%
4. Balance Sheet & Cash Flow AHCO
Cash Generation (TTM) N/A $82M
Cash Flow Margin N/A 2.4%
Net Cash / Leverage N/A ROE $1.97B Net Debt (1.67x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AHCO
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile N/A (N/A) 66.9% (12th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat AHCO
OpEx & R&D Intensity N/A 14.4% of Rev ($495M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AXNX (2) vs AHCO (8)
Institutional Metric AXNX AHCO Criterion Row Edge
Market Capitalization
Scale
N/A $989.8M Larger Scale AHCO
Trailing P/E Ratio
Valuation
N/M 7.8x Lower Multiple AHCO
Forward P/E Ratio
Valuation
N/M 7.8x Lower Multiple AHCO
Revenue Growth (YoY)
Growth
N/A +10.9% Higher Growth AHCO
Operating Margin (TTM)
Profitability
N/A 3.8% Higher Margin AHCO
Net Profit Margin
Profitability
N/A -11.8% Higher Margin AHCO
Return on Equity (ROE)
Capital Efficiency
N/A -28.4% Higher ROE AHCO
52-Week Range Position
Momentum
50% ($0–$1) 24% ($5–$13) Stronger Trend AXNX
Beta / 30D Volatility
Risk Regime
N/A 0.17β · 67% Vol Lower Realized Risk AHCO
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 45.2 / 100 (HOLD) Higher Composite AXNX
Trailing 12M Revenue (USD)
Operating Scale
N/A $3.44B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 18.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $82M ($1.97B Net Debt (1.67x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AHCO +43.23 pp
AXNX: -26.54% · AHCO: +16.69%
3M Horizon AXNX +3.18 pp
AXNX: +16.92% · AHCO: +13.74%
6M Horizon AXNX +3.18 pp
AXNX: +16.92% · AHCO: +13.74%
1Y Horizon AXNX +3.18 pp
AXNX: +16.92% · AHCO: +13.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AXNX vs AHCO. Trailing 12-month operating profitability (AXNX N/A vs AHCO 3.8%) and valuation multiples (AXNX N/M vs AHCO 7.8x Forward P/E) are benchmarked directly in Pillar 4 below.

AXNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
AHCO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.44B
Gross Margin18.2%
Op. Margin3.8%
ROE / Fwd P/E-28.4% · 7.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AXNX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AXNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AHCO SURGE
6d in phase · OBV NEUTRAL
Current IV 66.9%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AXNX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AHCO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $989.8M market capitalization and 3.8% operating margin.
OpEx & R&D Reinvestment 14.4% of Rev ($495M)
90D Engineering Disclosures 0 Published

Investor FAQ AXNX vs AHCO Key Questions & Quantitative Answers

As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas AHCO carries 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin). Composite vs. Pillar Nuance: While AXNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. AHCO 45.2/100 HOLD), AHCO captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (3.8% vs. N/A operating margin) and revenue trajectory (+10.9% vs. N/A YoY).

AHCO leads the Growth & Scale pillar: AXNX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with AHCO at +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin). On trailing 12-month operating scale, AXNX generates N/A in USD-normalized revenue versus $3.44B for AHCO. In operating R&D and SG&A reinvestment, AXNX deploys N/A (0 90-day corporate R&D disclosures) versus 14.4% of Rev ($495M) (0 disclosures) for AHCO.

AHCO screens cheaper on headline valuation multiples. AXNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AXNX (N/A ROE) versus AHCO (-28.4% ROE) capital efficiency.

In options market volatility and institutional positioning, AXNX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.